HBV B型与C型基因感染与恩替卡韦或替诺福韦停药后复发的关联
一项回顾性研究纳入台湾460例无肝硬化的HBeAg阴性患者,均按APASL 2012指南标准停用恩替卡韦或替诺福韦酯(TDF)至少12个月,比较B型与C型HBV感染停药后的复发情况。结果显示B型基因感染者的病毒学复发、临床复发和再治疗比例均高于C型,停用TDF者复发率更高且更早。
要点
- HBeAg阴性患者停用恩替卡韦或TDF后,B型HBV感染的病毒学复发、临床复发及再治疗比例均高于C型。
- 停用TDF者的病毒学与临床复发率高于停用恩替卡韦者,且复发时间更早。
- 治疗结束时HBsAg≤100 IU/mL且为C型基因者,5年病毒学复发率19.2%、临床复发率15.4%。
核心结论
- HBeAg阴性患者停用恩替卡韦或TDF后,B型HBV感染者的病毒学复发、临床复发和再治疗比例均高于C型感染者。
研究设计与样本
- 回顾性研究,纳入台湾460例无肝硬化的HBeAg阴性患者,均停用恩替卡韦或TDF至少12个月,数据收集于2007年至2016年,全部符合APASL 2012指南停药标准。
- 停药后前6个月每1-3个月评估一次,之后每3个月评估一次直至末次就诊;HBsAg于治疗前、治疗12个月后及治疗结束时检测。
主要发现
- 全部患者及倾向性评分匹配患者中,B型基因感染者的病毒学复发、临床复发和再治疗比例均高于C型感染者。
- 全部患者及倾向性评分匹配患者中,停用TDF者的病毒学与临床复发率更高、复发时间更早。
- 多因素分析显示TDF治疗、高龄、B型基因及治疗结束时较高HBsAg水平与病毒学和临床复发独立相关。
- 治疗结束时HBsAg≤100 IU/mL且为C型基因者,5年病毒学复发率19.2%、临床复发率15.4%。
- 停药后HBsAg清除率、肝细胞癌发生率和肝功能失代偿发生率在B型与C型之间、恩替卡韦与TDF组间均无显著差异。
关键数值与推荐
- 病毒学复发定义为停药后血清HBV DNA>2000 IU/mL;临床复发定义为停药后丙氨酸氨基转移酶升高超过正常上限(40 U/L)2倍且HBV DNA>2000 IU/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We compared rates of relapse of hepatitis B virus (HBV) infection between patients with HBV genotype B vs genotype C infection after cessation of entecavir or tenofovir disoproxil fumarate (TDF) therapy. All patients included in the study were HB e antigen (HBeAg)-negative. METHODS: We performed a retrospective study of 460 HBeAg-negative patients without cirrhosis in Taiwan who had stopped entecavir or TDF treatment for at least 12 months; data were collected from 2007 through 2016. All patients fulfilled the stopping criteria proposed by the APASL 2012 guidelines. Patients were evaluated every 1-3 months during the first 6 months after stopping therapy and then every 3 months until their last hospital visit; HB surface antigen (HBsAg) was measured in serum samples collected before treatment, after 12 months of treatment, and at the end of treatment. Virologic relapse was defined as a serum level of HBV DNA >2000 IU/mL after the cessation of treatment; clinical relapse was defined as increase in alanine aminotransferase more than 2-fold the upper limit of normal (40 U/L) and level of HBV DNA >2000 IU/mL after stopping treatment. RESULTS: Significantly higher proportions of patients with HBV genotype B infection had virologic and clinical relapse and retreatment than patients with HBV genotype C infection, among all patients and among patients matched by propensity sore. Patients who discontinued TDF therapy had significantly higher rates and earlier times of virologic and clinical relapse than patients who discontinued entecavir therapy, among all patients and propensity score-matched patients. Multivariate analysis showed that TDF therapy, old age, HBV genotype B, and higher end of treatment HBsAg level were independently associated with virologic and clinical relapse. Five-year rates of virologic and clinical relapse were low (19.2% and 15.4%, respectively) in patients with a combination of end of treatment level of HBsAg of 100 IU/mL or less and HBV genotype C infection. Rates of off-therapy HBsAg loss, development of hepatocellular carcinoma, and hepatic decompensation did not differ significantly between patients with HBV genotypes B vs C infection or between the entecavir vs TDF groups. CONCLUSIONS: Higher proportions of HBeAg-negative patients with HBV genotype B infection have virologic and clinical relapse and retreatment than patients with HBV genotype C infection, after cessation of entecavir or TDF therapy.
引用
- Chiu SM, Kuo YH, Wang JH, et al. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy. Clin Gastroenterol Hepatol. 2020. PMID: 32353534. doi:10.1016/j.cgh.2020.04.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。